“We write to emphasize the urgent need for Congress to take action," the Medical Group Management Association wrote to House and Senate leaders Dec. 19.
Telix Pharmaceuticals recently submitted its license application to the FDA for the investigational positron emission tomography agent TLX250-CDx (Zircaix).
With a theme of “Leading Through Change,” radiology’s flagship conference featured more than 850 research papers, 1,400 scientific posters and 1,600 educational exhibits.